Relay Therapeutics (RLAY) Accounts Payables (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Accounts Payables data on file, last reported at $4.1 million in Q1 2026.

• Quarterly Accounts Payables fell 51.43% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 51.43% YoY) and the FY2025 annual result came in at $7.7 million, down 45.34% from the prior year.
• Accounts Payables fell to $4.1 million in Q1 2026 per RLAY's latest filing, from $7.7 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.8 million in Q2 2023 and bottomed at $2.8 million in Q3 2025.
• The 5-year median for Accounts Payables is $8.4 million (2025), against an average of $8.8 million.
• The widest annual swing landed in 2023, when Accounts Payables soared 243.99%; it then sank 59.92% in 2025.
• Tracing RLAY's Accounts Payables over 5 years: stood at $10.6 million in 2022, then slipped by 12.92% to $9.2 million in 2023, then jumped by 53.05% to $14.1 million in 2024, then sank by 45.34% to $7.7 million in 2025, then tumbled by 46.74% to $4.1 million in 2026.
• Per Business Quant, the three latest RLAY Accounts Payables figures stand at $4.1 million (Q1 2026), $7.7 million (Q4 2025), and $2.8 million (Q3 2025).

Peer Comparison